First subjects dosed in Aptahem’s FIH study
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first healthy volunteers (HV) have been dosed in the clinical First in Human (FIH) study.The first HV subjects have now successfully been dosed in the randomized, placebo-controlled Phase 1 study which will evaluate the safety and tolerability of intravenous Apta-1 in healthy volunteers. For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA)